FuzzyBot: Importing a new version from external source

2024-02-12T10:46:17Z

Importing a new version from external source

New page

{{Short description|Class of medication}}
'''SGLT2 inhibitors,''' also called '''gliflozins''' or '''flozins''', are a class of medications that inhibit [[sodium-glucose transport proteins]] in the [[nephron]] (the functional units of the [[kidney]]), unlike [[SLC5A1|SGLT1 inhibitor]]s that perform a similar function in the [[intestinal mucosa]]. The foremost metabolic effect of this is to inhibit [[renal glucose reabsorption|reabsorption of glucose in the kidney]] and therefore lower [[blood sugar]]. They act by inhibiting [[sodium-glucose transport protein 2]] (SGLT2). SGLT2 inhibitors are used in the treatment of [[type 2 diabetes]]. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with [[type 2 diabetes]]. {{As of|2014}}, several medications of this class had been approved or were under development. In studies on [[canagliflozin]], a member of this class, the medication was found to enhance blood sugar control as well as reduce [[body weight]] and systolic and diastolic [[blood pressure]].

Translations:SGLT2 inhibitor/2/en - Revision history

FuzzyBot: Importing a new version from external source